Navigation Links
Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
Date:11/10/2008

this pathway in the development of most cancers, the evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis in patients with soft-tissue sarcoma, gastric, hepatocellular, endometrial, prostate, renal cell, head and neck cancers and hematological malignancies, as well as glioblastoma. The majority of tumors expressing high levels of pAkt were high-grade, advanced stage or had other features associated with poor prognosis. High pAkt is often seen in tumors that are resistant to conventional cancer treatments, including radiotherapy, chemotherapy, endocrine therapy, and especially therapy with some of the newer biologicals.

To date, over 1,700 patients have been treated with KRX-0401 in trials conducted both in the United States and Europe. Its safety profile is distinctly different from that of most cytotoxic agents. It does not appear to cause myelosuppression (depression of the immune system that may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of perifosine are nausea, vomiting, diarrhea and fatigue, but these are either mild or non-existent in lower doses that have induced tumor regression. Responses have been seen with both daily and weekly regimens. At the doses studied, the daily regimens were better tolerated.

In Phase 1/2 trials, KRX-0401 has induced tumor regressions and/or caused disease stabilization in a variety of tumor types. KRX-0401 has shown single agent partial responses in renal cell and hepatocel
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
2. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
6. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
7. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
8. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
9. Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
10. Lippincott Williams & Wilkins Selected as Publisher of the Journal of Neuroscience Nursing
11. Emdeon Selected by the Maryland Hospital Association to Power the Maryland Transaction Data Interchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 The global lab automation market ... $3,474.2 Million in 2014, at an estimated CAGR of ... lab automation market on the basis of equipment and ... On the basis of application, Lab Automation Market is ... proteomics solutions. Drug discovery is a major application of ...
(Date:5/5/2015)... New York, NY (PRWEB) May 05, 2015 The ... based on the experiences of Dr. Brad Reedy from ... When Judith Regan was asked why she chose to publish a ... me as a parent (and publisher) is the idea that it ... question...that we and our children are on the trek sometimes together ...
(Date:5/5/2015)... Skedans Systems a division of ... Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems ... developers, provides tooling to deliver real time information for ... Skedans Sensor Collaboration Platform is a single unified cloud ... Things, Web Real Time Communications (WebRTC), and commercial Unmanned ...
(Date:5/5/2015)... 05, 2015 Information Innovators ... serving the federal government, today announced its acquisition ... CCSi provides solutions exclusively to federal government customers ... in cyber security, health services, and program management ... industry-relevant credentials as a Third Party Assessment Organization ...
(Date:5/5/2015)... May 05, 2015 On May, 5, 2015, ... Charleston musician Irene Rose about alternatives for youngsters to do ... did you get the idea for starting a summer camp ... run an entertainment company called Once Upon a Party and ... lessons through songs and even scripture. We play games, sing, ...
Breaking Medicine News(10 mins):Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 3Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4Health News:My Positive Perspective Hosts Episode Informing People of a True Princess Summer Camp With Irene Rose 2
... has publicly apologized to sufferers of hepatitis after poking fun ... ,Peter Helliar had cracked a joke about Anderson ... ,Officials at Hepatitis Australia were annoyed at Helliar's 'cheap, cruel' ... present for Anderson on her 40th birthday. ...
... fifth-graders prefer larger portions of snacks and fast foods ... according to researchers at Dalhousie University in Canada. ... of portion sizes of french fries, meat, cooked vegetables ... usual portion sizes. , More than 63 ...
... founded in 2004 to bring high performance surgical sealants ... that vascular surgeons at the Krankenhaus Friedrichstadt in Dresden, ... high performance vascular sealant, ArterX(TM). ,The ... man suffering from vascular insufficiency of the leg requiring ...
... is close to developing the world's first vaccine against dengue ... news report said Friday. ,Clinical tests on up ... Thailand, said Jean Stephenne, GlaxoSmithKline Biologicals president. ,"We've ... for 10 years, more or less," The Straits Times quoted ...
... Australia have developed a garment with integrated electronic technology ... wirelessly. ,When placed on electronic hangers, ... a computer in the wardrobe. So theres no need ... is being cleaned, according to Professor Bruce Thomas, Director ...
... have found that HIV/AIDS and kidney transplant patients are ... cancer than the general population. ,The ... by Professor Andrew Grulich at the University of New ... Research (NCHECR). ,As part of the study, ...
Cached Medicine News:Health News:Tenaxis Medical Inc. Announces First Human Use of Vascular Sealant 2Health News:An Electronic Shirt That Monitors Your Hearts Health 2
(Date:5/5/2015)... 2015 Research and Markets ( ... "Clinical Laboratory,Molecular Diagnostics and Genomic Testing Services ... Asia Pacific Version" report to their offering. ... growing. Clinical laboratory testing is positioned to directly ... A range of dynamic trends are pushing market ...
(Date:5/5/2015)... state at a time, more cannabis entrepreneurs are coming up with brilliant ways to help cannabis business solve problems and capitalize ... ... ... ... Photo - ...
(Date:5/5/2015)... 5, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... randomized, double-blinded, placebo-controlled Phase 2 clinical trial of ... in combination with nab-paclitaxel and gemcitabine, versus nab-paclitaxel ... pancreatic cancer who have high serum levels of ... fourth leading cause of cancer death in ...
Breaking Medicine Technology:Asia Pacific Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Report 2015-2019 2Top Ten Ways Cannabis Startups are Getting Funded 2Top Ten Ways Cannabis Startups are Getting Funded 3Top Ten Ways Cannabis Startups are Getting Funded 4Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 2Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 3Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 4
... ANNAPOLIS, Md., April 28 /PRNewswire-FirstCall/ -- PharmAthene, ... company developing medical countermeasures against biological and chemical threats, ... call for investors on Wednesday, April 29th beginning at ... rPA anthrax vaccine program. The dial-in number within the ...
... Urological Association Annual Meeting --SEATTLE and CHICAGO, April ... DNDN ) today presented preclinical data demonstrating ... molecule, which targets TRPM8 (a transmembrane cation channel ... D-3263 demonstrated the ability to reduce BPH alone ...
Cached Medicine Technology:PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program 2Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 2Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 3Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia 4
Inquire...
Inquire...
Agarose I (Molecular Biology Grade) - A regular melting temperature agarose for electrophoresis requiring an exceptional level of purity with unequaled performance....
... a premium agarose used for isolating DNA ... produces clear sharp bands, with no smearing ... UltraClean Forensic Agarose is tested and certified ... activity and DNA contamination. Meets ...
Medicine Products: